


Number at risk

TARE	62	36	27	17	9	7	6	4	1
TKI	36	10	3	1	1	0	0	0	0


A Unmatched, Vp1 + Vp2 subgroup



Number at risk

TARE	62	34	15	10	6	4	2
TKI	56	12	4	2	1	1	1


B Unmatched, Vp3 subgroup



Number at risk

TARE	62	36	27	17	9	7	6	4	1
TKI	36	10	3	1	1	0	0	0	0

C IPTW, Vp1 + Vp2 subgroup



Number at risk

TARE	62	34	15	10	6	4	2
TKI	56	12	4	2	1	1	1

D IPTW, Vp3 subgroup

Supplementary Figure 1. Comparison of OS in subgroup analyses according to the level of PVTT. OS was compared between patients with Vp1 or Vp2 PVTT and those with Vp3 PVTT in an unmatched cohort (A, B) and a balanced cohort using IPTW (C, D). IPTW, inverse probability of treatment weighting; OS, overall survival; PVTT, portal vein tumor thrombosis; TARE, transarterial radioembolization; TKI, tyrosine kinase inhibitor.